Synthesis and pharmacological evaluation of Tic-hydantoin derivatives as selective σ1 ligands. Part 2

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 21, 2005, Pages 4828-4832

  Gassiot, Amaury Cazenave ^a,b   Charton, Julie ^a,c   Girault Mizzi, Sophie ^a   Gilleron, Pauline ^a,c   Debreu Fontaine, Marie Ange ^a   Sergheraert, Christian ^a   Melnyk, Patricia ^a  

^a CNRS   (France)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIV LILLE   (France)

Author keywords

Hydantoin; Selectivity; Tic; Receptors

Indexed keywords

HALOPERIDOL; HYDANTOIN DERIVATIVE; SIGMA 1 OPIATE RECEPTOR; SIGMA RECEPTOR LIGAND; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; EMBRYO; GUINEA PIG; HUMAN; HUMAN CELL; IC 50; NONHUMAN; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

EID: 25144477982     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.07.039     Document Type: Article

References (22)

1. W.D. Bowen Pharm. Acta. Helv. 74 2000 211
2. K. Senda, K. Matsuno, K. Okamoto, T. Kobajashi, K. Nakata, and S. Mita Eur. J. Pharmacol. 315 1996 1
3. K. Senda, K. Matsuno, T. Kobajashi, M. Nakazawa, K. Nakata, and S. Mita Pharmacol. Biochem. Behav. 59 1998 129
4. H. Kamei, Y. Noda, T. Kameyama, and T. Nabeshima Eur. J. Pharmacol. 319 1997 165
5. R. Bergeron, C. de Montigny, and G.J. Debonnel Neurosci. 16 1996 1193
6. T. Maurice, and A. Privat Eur. J. Pharmacol. 328 1997 9
7. G. Skuza Pol. J. Pharmacol. 55 2003 923
8. T. Maurice, R. Martin-Fardon, P. Romieu, and R.R. Matsumoto Neurosci. Biobehav. Rev. 26 2002 499
9. X. Guitart, X. Codony, and X. Monroy Psychopharmacology 174 2004 301
10. S.Y. Ablordeppey, J.B. Fischer, M. El-Ashmawy, and R.A. Glennon Eur. J. Med. Chem. 33 1998 625
11. See previous article.
12. S.Y. Ablordeppey, J.B. Fischer, and R.A. Glennon Bioorg. Med. Chem. 8 2000 2105
13. S.Y. Ablordeppey, J.B. Fischer, H. Law, and R.A. Glennon Bioorg. Med. Chem. 10 2002 2759
14. J. Charton, S. Delarue, S. Vendeville, M.-A. Debreu-Fontaine, S. Girault-Mizzi, and C. Sergheraert Tetrahedron Lett. 42 2001 7559
15. J. Charton, A. Cazenave Gassiot, P. Melnyk, S. Girault-Mizzi, and C. Sergheraert Tetrahedron Lett. 45 2004 7081
16. 18
17. W.D. Bowen, B.R. de Costa, S.B. Hellewell, M. Walker, and K.C. Rice Mol. Neuropharmacol. 3 1993 117
18. M.E. Ganapathy, P.D. Prasad, W. Huang, P. Seth, F.H. Leibach, and V. Ganapathy J. Pharmacol. Exp. Ther. 289 1999 251
19. 4 buffer (pH 7.5) for 120 min at 22°C. Non-specific binding was determined under similar conditions but in the presence of 10 μM unlabeled haloperidol.
20. 50 values from competitive inhibition experiments were determined using the Marquardt-Levenberg nonlinear curve fitting procedure of Xfit macro (Microsoft Excel).
21. T. Mossman J. Immunol. Methods 65 1983 55
22. R.A. Glennon, A.M. Ismaiel, S.A. Ablordeppey, M. El-Ashmawy, and J.B. Fisher Bioorg. Med. Chem. Lett. 14 2004 2217